

#### Instructi ns

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

#### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

### Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent

ADD



# ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1.						
Section 1.	Identifying Inforn	nation				
1. Given Name (Fir peter	st Name)	2. Surname (Last Na ulrichts	me)		3. Date 27-March-2018	
4. Are you the cor	responding author?	Yes No				
5. Manuscript Title FcRn-antagonist	e efgartigimod safely a	nd sustainably reduc	es IgGs in huma	า		
6. Manuscript Iden 97911-JCI-CMED-	ntifying Number (if you kn -RV-2	nowit)				
Section 2.						
Section 2.	The Work Under	Consideration for	Publication			
any aspect of the s statistical analysis,	submitted work (includir etc.)?	ng but not limited to gr	ants, data monitor		commercial, private foundation, edudy design, manuscript preparatio	
If yes, please fill o	evant conflicts of interoput the appropriate info out the appropriate info pe removed by pressing	ormation below. If yo	No u have more than	one entity p	press the "ADD" button to add a	row.
Name of Instituti			Non-Financial Support?	Other? Co	omments	
argenx				<b>✓</b> er	mployee	×
						ADD
Section 3.	Relevant financia	l activities outside	e the submitte	d work.		
of compensation	) with entities as desc	ribed in the instruction	ons. Use one line	for each enti	relationships (regardless of am ity; add as many lines as you nee 36 months prior to publication	ed by
Are there any rele	evant conflicts of intere	est? 🗸 Yes	No			
If yes, please fill o	out the appropriate info	ormation below.				
Name of Entity		Grant? Personal Fees?	Non-Financial Support?	Other? Co	omments	
nrgenx				<b>✓</b> er	mployee	×



Section 4							
Section 4. Intellectual I	Property	Patents	& Copyrig	hts			
Do you have any patents, wheth If yes, please fill out the appropri Excess rows can be removed by p	ate informat	ion belov	v. If you have	=		Yes No	a row.
Patent?	Pending?	Issued?	Licensed?	Royalties	Licensee?	Comments	
FcRn antagonists and methods of use (US 2015_0218239)		V			argenx n.v. and the board of reagents of the university of texas system		×
Methods Of Reducing Serum Levels Of Fc-containing Agents Using Fcrn Antagonists (US 2016/0264669 A1)		~			argenx N.V.		×
							ADD
Are there other relationships or a potentially influencing, what you Yes, the following relationships/condidate the time of manuscript accept On occasion, journals may ask au	ps/condition tions/circum	t readers submitte s/circums stances tl	could percei ed work? stances are p hat present a	oresent (exp a potential o confirm and	olain below): conflict of interest , if necessary, upd	ate their disclosure state	ements.
Section 6. Disclosure S	itatement						
Based on the above disclosures, below.  Generate Disclosure Statem  Dr. ulrichts reports other from a	this form wi		, -	rate a disclo	osure statement, v	which will appear in the b	оох



#### **Evaluati** in and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### Instructi ins

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

#### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency **Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

 $\textbf{Royalties:} \ \mathsf{Funds} \ \mathsf{are} \ \mathsf{coming} \ \mathsf{in} \ \mathsf{to} \ \mathsf{you} \ \mathsf{or} \ \mathsf{your} \ \mathsf{institution} \ \mathsf{due} \ \mathsf{to} \ \mathsf{your}$ 

patent

Guglietta 1



Section 1. Identifying Infor	mation		
Given Name (First Name) Antonio	2. Surname (Last Name) Guglietta		3. Date 27-March-2018
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Aut	hor's Name
5. Manuscript Title FcRn-antagonist efgartigimod safely	and sustainably reduces Ig0	Gs in human	
6. Manuscript Identifying Number (if you k 97911-JCI-CMED-RV-2	now it)	_	
Section 2. The Work Under			
The Work Under	<b>Consideration for Publ</b>	lication	
Did you or your institution at any time reco any aspect of the submitted work (includ statistical analysis, etc.)? Are there any relevant conflicts of inte	ing but not limited to grants, o		ent, commercial, private foundation, etc.) f d, study design, manuscript preparation,
	formation below. If you have	e more than one ent	ity press the "ADD" button to add a row
Name of Institution/Company	Grant? Personal Non-I	Financial Other	Comments
argenx			employee
			A
Section 3. Relevant financia	al activities outside the	submitted work	
	cribed in the instructions. U	se one line for each	ncial relationships (regardless of amour entity; add as many lines as you need b :he 36 months prior to publication.
Are there any relevant conflicts of inte	rest? 🗸 Yes 🗌 No		
If yes, please fill out the appropriate in	formation below.		
Name of Entity	Grant? Personal Non-I	Financial upport? Other	? Comments
argenx			employee
			Al

Guglietta 2



Section 4.	Intellectual Property Patents & Copyrights
Do you have any p	patents, whether planned, pending or issued, broadly relevant to the work? Yes V
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of cing, what you wrote in the submitted work?
Yes, the follow	ring relationships/conditions/circumstances are present (explain below):
✓ No other relat	ionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. nals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the above below.	ve disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Disc	losure Statement
Dr. Guglietta repo	orts other from argenx, during the conduct of the study; other from argenx, outside the submitted work; .

#### **Evaluati** in and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Guglietta 3



#### Instructi ins

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

#### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Inform	ation					
1. Given Name (Fir Torsten	st Name)	2. Surname Dreier	(Last Name)			3. Date 27-March-2018	
4. Are you the corr	esponding author?	Yes	<b>✓</b> No	Correspon Peter Ulric	-	or's Name	
5. Manuscript Title FcRn-antagonist	efgartigimod safely ar	nd sustainab	ly reduces Ig	Gs in humar	l		
6. Manuscript Iden 97911-JCI-CMED-	tifying Number (if you kno RV-2	ow it)		_			
Section 2							
Section 2.	The Work Under C	onsiderati	ion for Pub	lication			
any aspect of the s statistical analysis,	ubmitted work (includin	g but not limi	ted to grants,		_	nt, commercial, private foundatior study design, manuscript prepar a	
	out the appropriate info be removed by pressing			e more than	one entity	y press the "ADD" button to add	a row.
Name of Institut	on/Company	Grant	ersonal Non- Fees?	Financial Support?	Other?	Comments	
argenx					V	CDO of the company	×
							ADD
Section 3.	Relevant financial	activities	outside the	submitte	d work.		
of compensation clicking the "Add	) with entities as descr +" box. You should re	ibed in the ir port relation	nstructions. Unships that we	lse one line f	or each e	ial relationships (regardless of a ntity; add as many lines as you i e 36 months prior to publicati	need by
	evant conflicts of intere out the appropriate info						
Name of Entity			ersonal Non- Fees	Financial Support?	Other?	Comments	
argenx					~	CDO of the company	×
							ADD



Section 4. Intellectual	Property	Patents	& Copyrig	hts			
Do you have any patents, wheth If yes, please fill out the appropri Excess rows can be removed by p	ate informat	ion belov	v. If you hav			✓ Yes No the "ADD" button to add a ro	ow.
Patent?	Pending?	Issued?	Licensed?	Royalties	Licensee?	Comments	
FcRn antagonists and methods of use (US 2015_0218239)		V			argenx n.v. and the board of reagents of the university of texas system		×
Methods Of Reducing Serum Levels Of Fc-containing Agents Using Fcrn Antagonists (US 2016/0264669 A1)		~			argenx N.V.		×
							ADD
Section 5. Relationshi	ps not cov	ered ab	ove				
Are there other relationships or a potentially influencing, what you			-	ive to have i	nfluenced, or that	give the appearance of	
Yes, the following relationshi	ps/condition	s/circums	stances are i	oresent (exp	lain below):		
No other relationships/condi	•		-				
At the time of manuscript accept On occasion, journals may ask au	-						nts.
, <b>, ,</b> ,							
Section 6. Disclosure 9							
Disclosure 3							
Based on the above disclosures, below.	this form wi	ll automa	tically gene	rate a disclo	osure statement, v	which will appear in the box	
Generate Disclosure Statem	ent						
Dr. Dreier reports other from arg addition, Dr. Dreier has a patent board of reagents of the univers Agents Using Fcrn Antagonists (U	FcRn antago	nists and ystem, ar	methods of a patent N	use (US 201 Methods Of	15_0218239) issue	ed to argenx n.v. and the	



#### **Evaluati** in and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### Instructi ins

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

#### The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

### Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

van Bragt 1

ADD



# ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1.	Identifying Inform	nation			
1. Given Name (Fir Tonke	rst Name)	2. Surname (Last Name van Bragt	·)	3. Date 27-March-2018	
4. Are you the cor	responding author?	Yes 🗸 No	Corresponding Peter Ulrichts	; Author's Name	
5. Manuscript Title FcRn-antagonist		nd sustainably reduces	IgGs in human		
6. Manuscript Ider 97911-JCI-CMED	ntifying Number (if you kn -RV-2	owit)			
Section 2.					
Section 2.	The Work Under (	Consideration for Pu	ublication		
any aspect of the statistical analysis	submitted work (includir	ng but not limited to grant	ts, data monitoring b	ernment, commercial, private foundation, e poard, study design, manuscript preparation	
If yes, please fill o		ormation below. If you h		entity press the "ADD" button to add a	row.
Name of Institut	tion/Company	Grant? Personal No	on-Financial Support? Ot	her? Comments	
argenx bvba				consultant to argenx	×
argenx bvba				consultant to argenx	X ADD
argenx bvba				consultant to argenx	
Section 3.	Relevant financia	activities outside t	he submitted w		
Section 3.  Place a check in tof compensation	the appropriate boxes n) with entities as desci	activities outside to indicate with the table to indicate with the instructions.	whether you have f s. Use one line for e		ADD nount red by
Section 3.  Place a check in to f compensation clicking the "Add	the appropriate boxes n) with entities as desci	l activities outside to in the table to indicate wribed in the instructions eport relationships that	whether you have f s. Use one line for e were <b>present dur</b>	rork. Financial relationships (regardless of an each entity; add as many lines as you ne	ADD nount red by
Section 3.  Place a check in to of compensation clicking the "Add Are there any relations and the section of th	the appropriate boxes n) with entities as descr d +" box. You should re	I activities outside to in the table to indicate white the instructions export relationships that est?	whether you have f s. Use one line for e were <b>present dur</b>	rork. Financial relationships (regardless of an each entity; add as many lines as you ne	ADD nount red by
Section 3.  Place a check in to of compensation clicking the "Add Are there any relations and the section of th	the appropriate boxes  n) with entities as described  d +" box. You should re- evant conflicts of interes	I activities outside to in the table to indicate white the instructions export relationships that est?	whether you have for e s. Use one line for e were <b>present dur</b> o	rork. Financial relationships (regardless of an each entity; add as many lines as you ne	ADD nount red by

van Bragt 2



Section 4. Intellectual Property Patents & Copyrights	
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes V	
Section 5. Relationships not covered above	
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?	
Yes, the following relationships/conditions/circumstances are present (explain below):	
No other relationships/conditions/circumstances that present a potential conflict of interest	
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.	
Section 6. Disclosure Statement	
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.	
Generate Disclosure Statement	
Dr. van Bragt reports personal fees from argenx bvba, during the conduct of the study; other from SDD consulting B.V., outside the submitted work; .	

#### **Evaluati** in and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

van Bragt 3



#### Instructi ns

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

#### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent

Hanssens 1



Section 1. Identifying				
Identifying	Information			
1. Given Name (First Name) Valérie	2. Surname (Last Name) Hanssens		3. Date 27-March-201	8
4. Are you the corresponding auth	or? Yes 🗸 No	Correspond Peter Ulric	ling Author's Name hts	
5. Manuscript Title FcRn-antagonist efgartigimod	safely and sustainably reduces	lgGs in human		
6. Manuscript Identifying Number (97911-JCI-CMED-RV-2	(if you know it)			
Section 2. The Work L	Inder Consideration for Pu	blication		
Did you or your institution at any ti any aspect of the submitted work statistical analysis, etc.)? Are there any relevant conflicts If yes, please fill out the appropriences rows can be removed by	(including but not limited to grant of interest?  Yes  Notice information below. If you have	s, data monitorir	ng board, study design, manuscri	ipt preparation,
Name of Institution/Company	Grant? Personal No	n-Financial Support	Other? Comments	
argenx			<b>✓</b> employee	×
				ADD
Section 3. Relevant fi	nancial activities outside tl	ne submitted	l work.	
Place a check in the appropriate of compensation) with entities clicking the "Add +" box. You sl Are there any relevant conflicts If yes, please fill out the appropriate of the state of t	as described in the instructions nould report relationships that of interest?	. Use one line fo were <b>present c</b>	or each entity; add as many lin	es as you need by
Name of Entity	Grant? Personal No	n-Financial Support	Other? Comments	
argenx			<b>✓</b> employee	×
				ADD

Hanssens 2



Section 4.	ntellectual Property Patents & Copyrights				
Do you have any p	atents, whether planned, pending or issued, broadly relevant to the work? Yes V				
Section 5.	Relationships not covered above				
	ationships or activities that readers could perceive to have influenced, or that give the appearance of cing, what you wrote in the submitted work?				
Yes, the follow	ing relationships/conditions/circumstances are present (explain below):				
✓ No other relation	No other relationships/conditions/circumstances that present a potential conflict of interest				
	uscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. als may ask authors to disclose further information about reported relationships.				
Section 6.	Disclosure Statement				
Based on the abov below.	e disclosures, this form will automatically generate a disclosure statement, which will appear in the box				
Generate Discl	osure Statement				
Dr. Hanssens repo	orts other from argenx, during the conduct of the study; other from argenx, outside the submitted work; .				

#### **Evaluati** in and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Hanssens 3



#### Instructi ns

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

1

Hofman



Section 1.		nation.			
	Identifying Inforr	nation			
1. Given Name (Fir Erik	rst Name)	2. Surname (Last Nar Hofman	me)	3. Date 27-March-2018	
4. Are you the cor	responding author?	Yes V No	Correspoi Peter Ulr	nding Author's Name ichts	
<ol><li>Manuscript Title FcRn-antagonist</li></ol>	e efgartigimod safely a	nd sustainably reduc	es IgGs in huma	n	
6. Manuscript Ider 97911-JCI-CMED	ntifying Number (if you kn -RV-2	now it)			
Section 2.	The Work Under	Consideration for	Publication		
any aspect of the s statistical analysis, Are there any rele If yes, please fill o	submitted work (including etc.)? evant conflicts of interes	est?   Yes   ormation below. If you	nts, data monito	(government, commercial, private for ing board, study design, manuscripe to one entity press the "ADD" button	ot preparation,
Name of Institut	ion/Company	Grant? Personal I	Non-Financial Support	Other? Comments	
argenx				<b>✓</b> employee	×
					ADD
Section 3.	Relevant financia	l activities outside	the submitte	ed work.	
of compensation clicking the "Add Are there any rele	) with entities as desc	ribed in the instructio eport relationships th est?	ns. Use one line	ave financial relationships (regai for each entity; add as many line during the 36 months prior to p	es as you need by
Name of Entity		Grant? Personal I	Non-Financial Support?	Other? Comments	
argenx				<b>✓</b> employee	×
					ADD

Hofman 2



Section 4.	ntellectual Property Patents & Copyrights
Do you have any pa	etents, whether planned, pending or issued, broadly relevant to the work? Yes V No
Section 5.	Relationships not covered above
	ationships or activities that readers could perceive to have influenced, or that give the appearance of ing, what you wrote in the submitted work?
Yes, the following	ng relationships/conditions/circumstances are present (explain below):
✓ No other relation	onships/conditions/circumstances that present a potential conflict of interest
	uscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. als may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the above below.	e disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Disclo	osure Statement
Dr. Hofman report	s other from argenx, during the conduct of the study; other from argenx, outside the submitted work; .

#### **Evaluati** in and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Hofman 3



#### Instructi ons

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

#### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

### Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

 $\textbf{Royalties:} \ \mathsf{Funds} \ \mathsf{are} \ \mathsf{coming} \ \mathsf{in} \ \mathsf{to} \ \mathsf{you} \ \mathsf{or} \ \mathsf{your} \ \mathsf{institution} \ \mathsf{due} \ \mathsf{to} \ \mathsf{your}$ 

patent

Vankerckhoven 1



Section 1. Identifying Infor	mation			
1. Given Name (First Name) Bernhardt	2. Surname (Last Name) Vankerckhoven		3. Date 27-March-2018	
4. Are you the corresponding author?	Yes V No	Correspond Peter Ulrich	ing Author's Name nts	
5. Manuscript Title FcRn-antagonist efgartigimod safely	and sustainably reduces Ig	Gs in human		
6. Manuscript Identifying Number (if you keep 197911-JCI-CMED-RV-2	know it)	_		
Section 2				
Section 2. The Work Under	Consideration for Pub	lication		
Did you or your institution at any time recommendate any aspect of the submitted work (include statistical analysis, etc.)?  Are there any relevant conflicts of intellif yes, please fill out the appropriate in	ing but not limited to grants, rest?  Yes No formation below. If you hav	data monitorin	g board, study design, manuscript	preparation,
Excess rows can be removed by pressing	ng the "X" button.			
Name of Institution/Company	Grant? Personal Non-Fees? S	Financial Support?	Other? Comments	
argenx			employee	×
				ADD
Section 3. Relevant financia	al activities outside the	submitted	work.	
Place a check in the appropriate boxe of compensation) with entities as des clicking the "Add +" box. You should it	cribed in the instructions. U	lse one line fo	r each entity; add as many lines	as you need by
Are there any relevant conflicts of inte	rest? 🗸 Yes 🗌 No			
If yes, please fill out the appropriate in	formation below.			
Name of Entity	Grant? Personal Non-	Financial Support?	Other? Comments	
argenx			<b>✓</b> employee	×
				ADD

Vankerckhoven 2



Section 4.	Intellectual Property Patents & Copyrights
Do you have any p	patents, whether planned, pending or issued, broadly relevant to the work? Yes V
Section 5.	Relationships not covered above
	lationships or activities that readers could perceive to have influenced, or that give the appearance of cing, what you wrote in the submitted work?
Yes, the follow	ing relationships/conditions/circumstances are present (explain below):
✓ No other relat	ionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. nals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the above below.	ve disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Disc	losure Statement
Dr. Vankerckhove work; .	n reports other from argenx , during the conduct of the study; other from argenx , outside the submitted

#### **Evaluati** in and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Vankerckhoven 3



#### Instructi ns

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

#### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent

Verheesen 1



Section 1. Identify	ying Information					
Given Name (First Name)  Peter	2. Surnan Verheese	e (Last Name) en			3. Date 27-March-2018	
4. Are you the corresponding	gauthor? Yes	<b>✓</b> No	Correspond Peter Ulric	_	r's Name	
5. Manuscript Title FcRn-antagonist efgartigir	mod safely and sustaina	bly reduces IgG	s in human			
6. Manuscript Identifying Nun 97911-JCI-CMED-RV-2	nber (if you know it)					
Section 2						
Section 2. The Wo	ork Under Considera	tion for Publi	cation			
any aspect of the submitted v statistical analysis, etc.)? Are there any relevant conf	work (including but not linflicts of interest?	nited to grants, des No low. If you have	ata monitorir	ng board, si	t, commercial, private foundation tudy design, manuscript prepara	ation,
Name of Institution/Comp	2	Personal Non-F	inancial	Other?	Comments	
argenx				<b>v</b>	employee	×
						ADD
Section 3. Relevan	nt financial activities	outside the	submitted	l work.		
of compensation) with ent	ities as described in the	instructions. Us	se one line fo	or each en	al relationships (regardless of tity; add as many lines as you a <b>36 months prior to publicat</b>	need by
Are there any relevant conf						
If yes, please fill out the app	propriate information be	low.				
Name of Entity	Grant?	Personal Non-F	inancial	Other?	Comments	
argenx				<b>✓</b>	employee	×
<u> </u>						ADD

Verheesen 2



Section 4.	Intellectual Property Patents & Copyrights
Do you have any p	patents, whether planned, pending or issued, broadly relevant to the work? Yes V
Section 5.	Relationships not covered above
	lationships or activities that readers could perceive to have influenced, or that give the appearance of cing, what you wrote in the submitted work?
Yes, the follow	ing relationships/conditions/circumstances are present (explain below):
✓ No other relat	onships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. Hals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the above below.	ve disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Disc	losure Statement
Dr. Verheesen rep work; .	ports other from argenx, during the conduct of the study; other from argenx , outside the submitted

#### **Evaluati** in and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Verheesen 3



#### Instructi ins

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

### The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent



Section 1. Identifying Infor	mation			
1. Given Name (First Name) Nicolas	2. Surname (Last Name) Ongenae		3. Date 27-March-2018	
4. Are you the corresponding author?	Yes 🗸 No	Corresponding A	uthor's Name	
5. Manuscript Title FcRn-antagonist efgartigimod safely a	and sustainably reduces Ig	Gs in human		
6. Manuscript Identifying Number (if you k 97911-JCI-CMED-RV-2	now it)			
Section 2. The Work Under	Consideration for Pub	lication		
any aspect of the submitted work (includi statistical analysis, etc.)?  Are there any relevant conflicts of interior of the submitted in the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interior in the submitted in	rest?   Yes   No formation below. If you hav	e more than one e	ntity press the "ADD" button to add a	
, , , , , , , , , , , , , , , , , , ,	Fees? S	Support?		
argenx			former employee	×
				ADD
Section 3. Relevant financia	al activities outside the	submitted wo	rk.	
Place a check in the appropriate boxes of compensation) with entities as described clicking the "Add +" box. You should rare there any relevant conflicts of interesting the second conflicts of interesting the s	cribed in the instructions. Leport relationships that we rest?	Jse one line for eac	h entity; add as many lines as you ne	eed by
Name of Entity	Grant? Personal Non-	Financial Support? Othe	cr? Comments	
argenx			former employee	×
				ADD



Section 4. Intelle	ctual Property	Patents	& Copyrig	ghts			
Do you have any patents, If yes, please fill out the a Excess rows can be remov	ppropriate informa	tion belov	v. If you hav	-		✓ Yes	row.
Patent?	Pending?	Issued?	Licensed?	Royalties	Licensee?	Comments	
FcRn antagonists and method: (US 2015_0218239)	s of use	V			argenx n.v. and the board of reagents of the university of texas system		×
Methods Of Reducing Serum L Of Fc-containing Agents Using Antagonists (US 2016/026466)	g Fcrn	V			argenx N.V.		×
							ADD
Are there other relationsh potentially influencing, where the following relationships to the following relationships the following relationshi	hat you wrote in the stionships/conditions/circum	nt readers e submitte ns/circums nstances ti	could perce ed work? stances are   hat present	present (exp a potential o confirm and	lain below): conflict of interest , if necessary, upd	date their disclosure statem	ents.
Section 6. Disclo	sure Statement						
Based on the above disclobelow.  Generate Disclosure S  Dr. Ongenae reports other	Statement er from argenx , dui has a patent FcRn a the university of te	ill automa ring the co antagonist xas systen	onduct of the s and methon n, and a pate	e study; othe ods of use (L ent Methods	er from argenx, oo IS 2015_0218239)	which will appear in the bo utside the submitted work, issued to argenx n.v. and um Levels Of Fc-containing	



#### **Evaluati** in and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### Instructi ons

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

### Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Lykhopiy 1



Section 1. Identifying Infor	mation		
Given Name (First Name)  Valentina	2. Surname (Last Name) Lykhopiy		3. Date 27-March-2018
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Auth	nor's Name
5. Manuscript Title FcRn-antagonist efgartigimod safely	and sustainably reduces Ig	Gs in human	
6. Manuscript Identifying Number (if you k 97911-JCI-CMED-RV-2	now it)	_	
Section 2			
Section 2. The Work Under	<b>Consideration for Pub</b>	lication	
any aspect of the submitted work (includ statistical analysis, etc.)? Are there any relevant conflicts of inte	rest?  Yes  No	data monitoring board	ent, commercial, private foundation, etc.) fo , study design, manuscript preparation, ty press the "ADD" button to add a row.
Excess rows can be removed by pressir	ng the "X" button.		
Name of Institution/Company	Grant? Personal Non-	Financial Other	Comments
argenx n.v.			former employee
			AD
Section 3. Relevant financia	al activities outside the	submitted work	
of compensation) with entities as desc clicking the "Add +" box. You should r	cribed in the instructions. Use port relationships that we	se one line for each	cial relationships (regardless of amount entity; add as many lines as you need by he 36 months prior to publication.
Are there any relevant conflicts of inte			
If yes, please fill out the appropriate in	formation below.		
Name of Entity	Grant? Personal Non-	Financial Other	Comments
argenx n.v			former employee
			AD

Lykhopiy 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes V
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Generate Disclosure Statement
Ms. Lykhopiy reports that she had been an employee of argenx n.v. during the conduct of the study and during the 36 months prior to publication of the study.

#### **Evaluati** in and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Lykhopiy 3



#### Instructi ins

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

#### The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent

Enriquez 1



Section 1. Identifying Inform	nation		
Given Name (First Name)  F. Javier	2. Surname (Last Name) Enriquez		3. Date 27-March-2018
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Aut	hor's Name
5. Manuscript Title FcRn-antagonist efgartigimod safely a	nd sustainably reduces Ig0	Gs in human	
6. Manuscript Identifying Number (if you kn 97911-JCI-CMED-RV-2	owit)	_	
Continue			
Section 2. The Work Under (	Consideration for Publ	ication	
any aspect of the submitted work (includir statistical analysis, etc.)? Are there any relevant conflicts of intere	est?  Yes  No  Drmation below. If you have	lata monitoring board	ent, commercial, private foundation, etc.) for I, study design, manuscript preparation, ity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal Non-F	Cinancial other	Comments
argenx			former employee ×
			ADD
Section 3. Relevant financia	l activities outside the	submitted work	
	ribed in the instructions. Useport relationships that we lest?	se one line for each	ncial relationships (regardless of amount entity; add as many lines as you need by the 36 months prior to publication.
Name of Entity	Grant? Personal Non-F	Financial Other	Comments
argenx			former employee
			ADD

Enriquez 2



Section 4.	Intellectual Property Patents & Copyrights
Do you have any p	patents, whether planned, pending or issued, broadly relevant to the work? Yes V
Section 5.	Relationships not covered above
	lationships or activities that readers could perceive to have influenced, or that give the appearance of cing, what you wrote in the submitted work?
Yes, the follow	ing relationships/conditions/circumstances are present (explain below):
✓ No other relati	onships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. It is also may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the above below.	ve disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Discl	osure Statement
Dr. Enriquez repo	rts other from argenx, during the conduct of the study; other from argenx, outside the submitted work; .

#### **Evaluati** In and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Enriquez 3



#### Instructi ins

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Cho 1



Section 1.	Identifying Inform	nation			
1. Given Name (Fir JunHaeng	st Name)	2. Surname (Last Name) Cho		3. Date 27-March-20	018
4. Are you the cor	responding author?	Yes 🗸 No	Corresponding A Peter Ulrichts	author's Name	
5. Manuscript Title FcRn-antagonist		nd sustainably reduces	gGs in human		
6. Manuscript Ider 97911-JCI-CMED	ntifying Number (if you kno -RV-2	owit)			
	ı				
Section 2.	The Work Under C	Consideration for Pu	blication		
any aspect of the s statistical analysis, Are there any rela If yes, please fill o	submitted work (includin etc.)? evant conflicts of intere	ormation below. If you ha	, data monitoring bo	ard, study design, manus	cript preparation,
Name of Institut	ion/Company	Grant? Personal Nor	n-Financial Support?	er? Comments	
argenx		<b>V</b>			×
					ADD
Section 3.					
Section 3.	Relevant financial	activities outside th	e submitted wo	rk.	
of compensation clicking the "Add	) with entities as descr	n the table to indicate with the instructions. port relationships that vest? Yes V No	Use one line for ea	ch entity; add as many	lines as you need by to publication.
					ADD
Section 4.	Intellectual Proper	ty Patents & Copyr	ights		
Do you have any	patents, whether plan	ned, pending or issued,	oroadly relevant to	the work? Yes	<b>✓</b> No

Cho 2



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	ving relationships/conditions/circumstances are present (explain below):
<b>∨</b> No other relat	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. nals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
below.	ve disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Disc	closure Statement
Dr. Cho reports g	rants from argenx , during the conduct of the study; .

### **Evaluati** in and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Cho 3



#### Instructi ins

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent

Ober 1



Section 1. Identifying Inform	ation						
1. Given Name (First Name) Raimund J.	2. Surname (Last Name) Ober		3. Date 27-March-2018				
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Name Peter Ulrichts					
5. Manuscript Title FcRn-antagonist efgartigimod safely an	nd sustainably reduces Ig0	3s in human					
6. Manuscript Identifying Number (if you knows 97911-JCI-CMED-RV-2	ow it)						
Section 2. The Work Under C	onsideration for Publ	ication					
			ernment, commercial, private foundation, etc board, study design, manuscript preparation,				
Are there any relevant conflicts of intere	st? 🗸 Yes 🗌 No						
If yes, please fill out the appropriate info Excess rows can be removed by pressing		e more than on	e entity press the "ADD" button to add a ro	w.			
Name of Institution/Company	Grant? Personal Non-l	Financial upport?	ther? Comments				
argenx n.v.	V			×			
				AD			
Section 3. Relevant financial	activities outside the	submitted v	vork.				
of compensation) with entities as descri	ibed in the instructions. Uport relationships that we	se one line for	financial relationships (regardless of amoreach entity; add as many lines as you need ring the 36 months prior to publication.				
Are there any relevant conflicts of intere If yes, please fill out the appropriate info							
Are there any relevant conflicts of intere	rmation below.  Grant? Personal Non-l	Financial upport	ther? Comments				
Are there any relevant conflicts of intere If yes, please fill out the appropriate info	rmation below.  Grant? Personal Non-l	_  0	ther? Comments  R.J.O. is principal investigator on scientific research agreements	×			

Ober 2



Section 4.	Intellectual Property Patents & Copyrights
Do you have any	patents, whether planned, pending or issued, broadly relevant to the work? Yes V No
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	inuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. In als may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Dis	closure Statement
•	grants from argenx n.v., other from argenx n.v., during the conduct of the study; grants from Shire, grants outside the submitted work; .
Drs. Ward and O	ber are married, therefore please see in addition the spouse's statement.

### **Evaluati** in and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Ober 3



#### Instructi ins

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency **Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent



Section 1.	Identifying Inform	ation					
1. Given Name (Fir E. Sally	st Name)	2. Surnan Ward	ne (Last Nam	e)		3. Date 27-March-2018	
4. Are you the cor	responding author?	Yes	<b>✓</b> No	Correspond Peter Ulric	_	or's Name	
5. Manuscript Title FcRn-antagonist	efgartigimod safely an	d sustaina	ably reduce	s IgGs in human			
6. Manuscript Ider 97911-JCI-CMED	ntifying Number (if you kno -RV-2	wit)					
Section 2							
any aspect of the s statistical analysis, Are there any relo If yes, please fill o	submitted work (including etc.)? evant conflicts of interes	e payment g but not lin st?	or services fr mited to gran /es	rom a third party (g nts, data monitori	ng board,	nt, commercial, private foundation, e study design, manuscript preparatio y press the "ADD" button to add a	n,
Name of Institut				on-Financial Support?	Other?	Comments	
argenx n.v.		<b>V</b>					×
argenx n.v.					<b>v</b>	E.S.W has a financial interest in argenx	×
							ADD
Section 3.	Relevant financial	activitie	s outside	the submitted	d work.		
of compensation	) with entities as descri	bed in the	instruction	s. Use one line f	or each e	ial relationships (regardless of am ntity; add as many lines as you ned e 36 months prior to publication	ed by
Are there any rele	evant conflicts of interes	st? 🗸	res N	lo			
If yes, please fill o	out the appropriate info	rmation be	elow.				
Name of Entity		Grant?	Personal N Fees	on-Financial Support	Other?	Comments	
Shire		<b>v</b>				E.S.W. is principal investigator on scientific research agreements	×



Name of Entity	Gr	alit	sonal Non- ees?	Financial Support?	Other?	Comments		
Bioverativ		v					al investigator on	×
				Ш		scientific resear	cn agreements	ADD
Section 4. Intellectual I	Property	Patents	& Copyrig	thts				
Do you have any patents, wheth If yes, please fill out the appropri Excess rows can be removed by p	ate informat	ion below	v. If you hav	-				ow.
Patent?	Pending?	Issued?	Licensed?	Royalties	License	? Comr	nents	
GGI ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING FO FCRN RECEPTOR AND USES THEREOF (WO2006130834A3)			<b>v</b>	<b>v</b>	only partia known - Medimmur	reagent	by the board of s of the university of stem	×
FcRn antagonists and methods of use US 2015_0218239)		<b>v</b>	~	<b>v</b>	argenx n.v. others ?		by the board of s of the university of estem	×
Methods Of Reducing Serum Levels Of Fc-containing Agents Using Fcrn Antagonists (US 2016/0264669 A1)	<b>v</b>					the boar	by argenx n.v. and rd of reagents of the ty of texas system	×
								ADD
Section 5. Relationshi	ps not cov	ered ab	ove					
Are there other relationships or a potentially influencing, what you				ive to have i	nfluenced,	or that give the	e appearance of	
Yes, the following relationshi	ns/condition	s/circums	stances are i	oresent (exp	lain below	):		
No other relationships/condi	•			•				
At the time of many consists		المراكب الأسما		£: !	: <b>f</b>			-4-
At the time of manuscript accept On occasion, journals may ask au	-						r aisclosure stateme	nts.



#### Section 6.

### **Disclosure Statement**

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

#### **Generate Disclosure Statement**

Dr. Ward reports grants from argenx n.v., other from argenx n.v., during the conduct of the study; grants from Shire, grants from Bioverativ, outside the submitted work;

Drs. Ward and Ober are married, therefore please see in addition the spouse's statement.

### **Evaluati** In and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### Instructi ns

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Ide	entifying Inform	ation					
1. Given Name (First Na Hans	me)	2. Surnam de Haard	e (Last Name)			3. Date 27-March-2018	
4. Are you the correspo	nding author?	Yes	<b>✓</b> No	Correspond Peter Ulric	-	or's Name	
5. Manuscript Title FcRn-antagonist efga	nrtigimod safely an	d sustaina	bly reduces Ig0	Gs in human			
6. Manuscript Identifyir 97911-JCI-CMED-RV-2		w it)		_			
Section 2							
Section 2. The	e Work Under Co	onsidera	tion for Publ	ication			
any aspect of the subm statistical analysis, etc.) Are there any relevan	itted work (including ? t conflicts of interes	but not lin	es No	lata monitori	ng board,	nt, commercial, private foundation, study design, manuscript prepar at	ion,
If yes, please fill out the Excess rows can be re				e more than	one entity	y press the "ADD" button to add	a row.
Name of Institution/	Company	Grant?	Personal Non-l Fees ? S	Financial upport?	Other?	Comments	
argenx					V	CSO of the company	×
							ADD
Section 3. Rel	evant financial a	activities	outside the	submitted	d work.		
of compensation) wit	th entities as descril nox. You should rep t conflicts of interes	bed in the port relation tt?	instructions. U onships that we es \(\textstyle \text{No}\)	se one line f	or each ei	ial relationships (regardless of a ntity; add as many lines as you n e <b>36 months prior to publicatic</b>	eed by
Name of Entity		Grant?	Personal Non-l	inancial	Other?	Comments	
argenx					<b>V</b>	CSO of the company	×
			_				ADD



Section 4. Intellectual I	Property	Patents	& Copyrig	ghts			
Do you have any patents, wheth If yes, please fill out the appropri Excess rows can be removed by p	ate informat	ion below	v. If you hav	-		✓ Yes No the "ADD" button to add a re	ow.
Patent?	Pending?	Issued?	Licensed?	Royalties	Licensee?	Comments	
FcRn antagonists and methods of use (US 2015_0218239)		V			argenx n.v. and the board of reagents of the university of texas system		×
Methods Of Reducing Serum Levels Of Fc-containing Agents Using Fcrn Antagonists (US 2016/0264669 A1)		V			argenx N.V.		×
							ADD
Section 5. Relationshi	ps not cov	ered ab	ove				
Are there other relationships or a potentially influencing, what you  Yes, the following relationshi  No other relationships/condi	wrote in the	e submitte s/circums	ed work? stances are p	present (exp	lain below):		
At the time of manuscript accept On occasion, journals may ask au	-						nts.
Section 6. Disclosure S	tatement						
Based on the above disclosures, below.	this form wi	ll automa	tically gene	rate a disclo	osure statement, v	which will appear in the box	
Generate Disclosure Statem	ent						
Dr. de Haard reports other from In addition, Dr. de Haard has a p the board of reagents of the unit Agents Using Fcrn Antagonists (U	atent FcRn a versity of tex	ntagonist as system	s and methon, and a pate	ods of use (Lent Methods	JS 2015_0218239)	issued to argenx n.v. and	



### **Evaluati** in and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### Instructi ns

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Leupin 1



	l						
Section 1.	Identifying Inform	ation					
1. Given Name (Fir Nicolas	st Name)	2. Surnam Leupin	e (Last Name)			3. Date 27-March-2018	
4. Are you the cor	responding author?	Yes	<b>✓</b> No	Correspon Peter Ulric	-	or's Name	
5. Manuscript Title FcRn-antagonist	e efgartigimod safely ar	nd sustaina	bly reduces Ig	Gs in humar	1		
6. Manuscript Ider 97911-JCI-CMED	ntifying Number (if you kno -RV-2	ow it)		_			
Continue 2							
Section 2.	The Work Under C	Consideration	tion for Pub	lication			
any aspect of the statistical analysis Are there any rel	submitted work (includin , etc.)? evant conflicts of intere	g but not lim	es No	data monitori	ing board,	nt, commercial, private foundation, study design, manuscript preparati	on,
	out the appropriate info oe removed by pressing			e more than	one entity	y press the "ADD" button to add a	ı row.
Name of Institut	ion/Company	Grant?	Personal Non- Fees S	Financial upport?	Other?	Comments	
argenx					<b>v</b>	Chief medical officer at argenx	×
							ADD
Section 3.							
Section 5.	Relevant financial	activities	outside the	submitte	d work.		
of compensation clicking the "Add Are there any rel	ı) with entities as descr	ibed in the port relationst?	instructions. Unships that we es No	se one line f	or each e	ial relationships (regardless of ar ntity; add as many lines as you ne e 36 months prior to publicatio	eed by
Name of Entity		Grant?	Personal Non- Fees S	Financial Support?	Other?	Comments	
argenx					<b>v</b>	Chief medical officer at argenx	×
							ADD

Leupin 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes V
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  Generate Disclosure Statement
Dr. Leupin reports other from argenx , during the conduct of the study; other from argenx, outside the submitted work; .

### **Evaluati** in and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Leupin 3